News

The extension will remain open while Hemispherx submits an amended NDA, the company said. In the request for extension, the company advised the FDA of the findings of

The financial terms of the current agreement have not been disclosed. The contract covers initial activities in developing a controlled release formulation of an undisclosed compound using the

According to the company, the combined use of these two drugs has recently been evaluated in animals and showed improved blood glucose regulation when compared to the administration

The new improved Columbus 2.3 system is believed to provide faster and more powerful high content analysis-based research applications. The platform will now help scientists perform their high

The technology used to build Chiromics’ libraries, employs a chemical synthesis technique referred to as ‘cascade catalysis.’ According to the company, cascade catalysis helps create a diverse collection

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).

As per the collaboration, Camurus has granted Novartis an option to license the FluidCrystal Injection depot technology to develop, manufacture and commercialize Camurus’ octreotide product CAM2029 and related

The new solution, QTinno is intended to be used for an upcoming Thorough QT trial. According to the company, QTinno 3-D ECG software technology is a novel, fully

The national chain will be carrying two BluScience SKUs (HeartBlu and EternalBlu) by the end of first quarter of 2012. Two additional SKUs (MemoryBlu and Blu2Go) will also